Scientific Evidence of Xuebijing Injection in the Treatment of Sepsis

Table 1

Basic characteristics description.

Author, year	Country	Sample size	Treatment intervention	Control intervention	Quality assessment tool	Conclusion summary
Chen et al. [17] 2018	China	17 (1247)	XBJI + WM	WM	Cochrane criteria	The XBJI and ulinastatin combination therapy appeared to be more effective for the treatment of sepsis when compared with the use of ulinastatin alone.
Li et al. [18] 2018	China	16 (1144)	XBJI + WM	WM	Cochrane criteria	This study suggested that supplementation with XBJI in addition to the conventional treatment appeared to be more effective for the treatment of sepsis as compared to the conventional treatment alone.
Xiao et al. [19] 2018	China	16 (1335)	XBJI + WM	WM	Cochrane criteria	The combination therapy appeared to be more effective for the treatment of sepsis compared to the conventional treatment alone. It was also observed that the risk of adverse events did not increase.
Zheng et al. [20] 2018	China	16 (1192)	XBJI + WM	WM	Cochrane criteria	Our results found that XBJI when combined with ulinastatin was superior to both routine therapies and the single administration of either ulinastatin or XBJI.
Xiao et al. [21] 2017	China	49 (1801)	XBJI + WM	WM	Jadad	The combination therapy appeared to be more effective for the treatment of sepsis when compared to conventional treatment alone.
Liu et al. [22] 2021	China	16 (1423)	XBJI + WM	WM	Jadad	This study suggested that supplementation with XBJI in addition to the conventional treatment appeared to be more effective for the treatment of sepsis as compared to conventional treatment alone.
Zhang et al. [23] 2021	China	15 (930)	XBJI + WM	WM	Cochrane criteria	The utilization of XBJI has a certain effect on the improvement of the inflammatory response and increased level of platelets.
Zhou et al. [24] 2016	China	8 (399)	XBJI + WM	WM	Jadad	The homogeneity of the reduced mortality rate and the available evidence was sufficient to support the use of XBJI as adjunctive therapy for sepsis.
Li et al. [25] 2016	China	11 (803)	XBJI + WM	WM	Cochrane criteria	Clinical evidence showed that the addition of XBJI to the conventional treatment could improve the clinical efficacy in the treatment of sepsis.
Xu et al. [26] 2014	China	18 (1172)	XBJI + WM	WM	Jadad	The combined use of XBJI based on conventional treatment could improve the survival rate of patients with sepsis.
Li et al. [27] 2013	China	13 (1280)	XBJI + WM	WM	Jadad	XBJI had a certain effect in improving the inflammatory response and coagulation function in patients with sepsis. These effects reduced mortality and improved the APACHE II scores.
Sun et al. [28] 2012	China	18 (1080)	XBJI + WM	WM	Jadad	The existing results showed that the application of XBJI in the treatment of sepsis could significantly reduce the white blood cell count in the plasma of patients.
Hu et al, [29] 2010	China	25 (1970)	XBJI + WM	WM	Cochrane criteria	The evidence available showed that XBJI might decrease mortality, ineffectiveness, incidence of complication, and average hospital stay. It could also reduce the APACHE II score in patients with sepsis.
Wu et al. [30] 2020	China	14 (938)	XBJI + WM	WM	Cochrane criteria	XBJI can improve the clinical symptoms, significantly reduce the mortality, and has a high clinical application value.